RNA vs SRPT

Avidity Biosciences (RNA) continues to demonstrate strong 10x growth potential, sustained by its proprietary Antibody Oligonucleotide Conjugate (AOC) platform. The lead asset, AOC 1001 for Myotonic Dystrophy Type 1 (DM1), remains critically important, with the path to potential regulatory filing in late 2026/early 2027 still intact. This timeline, coupled with ongoing clinical progress for AOC 102...

Sarepta's 10x growth potential remains highly challenged by persistent commercial execution issues for Elevidys, reflected in Q4 2025's wider-than-expected loss and reduced 2026 revenue guidance ($1.2B-$1.4B from $1.86B in 2025). While recent initial Phase 1/2 siRNA data shows promise for future pipeline diversification and an sNDA for traditional approval of existing PMOs is planned, these bright...